Nurix Therapeutics Inc (NRIX) is a clinical-stage biopharmaceutical company that focuses on developing drugs to treat various diseases, including cancer and immune disorders, by modulating the ubiquitin system. The company's proprietary technology platform, DELigase, enables the discovery of small molecule drugs that selectively target E3 ligases, the key enzymes in the ubiquitin system. Nurix has several drug candidates in preclinical and clinical development stages.
One of Nurix's lead drug candidates, NX-2127, is a novel small molecule selective inhibitor of the CBL-B E3 ligase that plays a crucial role in the regulation of T-cell activation and immune response. The company is conducting a Phase 1/2 clinical trial of NX-2127 in patients with advanced solid tumors and lymphomas.
Nurix's other drug candidates include selective inhibitors of the BRD4 and BET family of bromodomain proteins, which are involved in the regulation of gene expression and have been implicated in various cancers and immune disorders. The company is also developing small molecule inhibitors of the E3 ligases responsible for the degradation of several key proteins involved in the pathogenesis of cystic fibrosis and other diseases.
Headquartered in San Francisco, California, Nurix was founded in 2015 and went public in 2020. The company has collaborations with several pharmaceutical companies, including Gilead Sciences, Sanofi, and Pfizer, to develop and commercialize its drug candidates.
|
